COO COOPER COMPANIES, INC.
Ophthalmic Goods · Nasdaq · SEC CIK 711404 · Fiscal year ends 10/31
Financial factors as of 2026-07-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.7%
TTM net income YoY39.8%
TTM EPS YoY42.6%
Revenue 3-yr CAGR6.4%
Net income 3-yr CAGR27.5%
Margins
Gross margin65.9%
Operating margin12.8%
Net margin13.5%
FCF margin16.0%
EBITDA margin19.7%
Returns
ROE6.8%
ROA4.6%
ROIC (approx.)5.1%
Asset turnover0.34x
Leverage & solvency
Liabilities / assets34.3%
Debt / equity0.31x
Current ratio1.22x
Interest coverage6.10x
Cash quality & payout
Operating cash flow / net income1.81x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue8.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-07-31 | 2026Q22026-04-30 | 2026Q12026-01-31 | 2025Q4*2025-10-31 | 2025Q32025-07-31 | 2025Q22025-04-30 | 2025Q12025-01-31 | 2024Q4*2024-10-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.07B | $1.08B | $1.02B | $1.07B | $1.06B | $1.00B | $964.70M | $1.02B |
| Cost of revenue | $354.30M | $346.10M | $328.90M | $414.30M | $368.30M | $323.20M | $304.50M | $340.70M |
| Gross profit | $711.90M | $735.40M | $695.20M | $650.80M | $692.00M | $679.10M | $660.20M | $677.70M |
| R&D expense | $41.60M | $42.50M | $44.30M | $41.40M | $44.60M | $45.50M | $40.70M | $37.70M |
| SG&A expense | $401.30M | $676.20M | $390.20M | $419.20M | $421.70M | $399.00M | $387.90M | $391.40M |
| Operating income | $222.00M | -$31.00M | $212.80M | $140.40M | $175.70M | $184.80M | $182.00M | $198.40M |
| Interest expense | $21.50M | $20.90M | $22.40M | $24.40M | $25.40M | $24.20M | $26.00M | $27.00M |
| Pretax income | $201.80M | -$48.40M | $192.20M | $116.80M | $151.90M | $144.50M | $153.30M | $168.60M |
| Income tax | -$231.00M | $29.50M | $61.40M | $32.20M | $53.60M | $56.80M | $49.00M | $51.10M |
| Net income | $432.80M | -$77.90M | $130.80M | $84.60M | $98.30M | $87.70M | $104.30M | $117.50M |
| EBITDA | $269.60M | $16.80M | $308.30M | $238.80M | $221.40M | $227.80M | $273.00M | $289.40M |
| EPS (basic) | 2.24 | -0.40 | 0.67 | — | 0.49 | 0.44 | 0.52 | — |
| EPS (diluted) | 2.24 | -0.40 | 0.66 | — | 0.49 | 0.44 | 0.52 | — |
| Weighted avg. shares (diluted) | 193.40M | 195.00M | 196.70M | — | 200.00M | 200.70M | 201.20M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $154.70M | $138.80M | $124.90M | $110.60M | $124.90M | $116.20M | $100.90M | $107.70M |
| Receivables | $788.90M | $809.20M | $807.10M | $829.00M | $792.30M | $780.90M | $716.40M | $717.00M |
| Inventory | $911.50M | $896.40M | $876.40M | $846.00M | $881.00M | $880.30M | $842.90M | $802.70M |
| Current assets | $2.28B | $2.30B | $2.13B | $2.11B | $2.14B | $2.13B | $1.99B | $1.95B |
| PP&E, net | $2.14B | $2.13B | $2.12B | $2.08B | $1.99B | $1.93B | $1.86B | $1.86B |
| Goodwill | $3.88B | $3.89B | $3.91B | $3.85B | $3.86B | $3.86B | $3.79B | $3.84B |
| Intangibles | $1.45B | $1.49B | $1.54B | $1.59B | $1.64B | $1.69B | $1.74B | $1.79B |
| Total assets | $12.67B | $12.48B | $12.42B | $12.39B | $12.38B | $12.41B | $12.22B | $12.32B |
| Current liabilities | $1.87B | $1.80B | $1.60B | $1.11B | $1.01B | $1.01B | $999.60M | $1.02B |
| Short-term debt | $628.10M | $598.90M | $620.70M | $47.80M | $46.90M | $59.80M | $48.70M | $33.30M |
| Long-term debt | $1.91B | $1.86B | $1.88B | $2.46B | $2.43B | $2.52B | $2.49B | $2.55B |
| Total debt | $2.54B | $2.46B | $2.50B | $2.50B | $2.48B | $2.58B | $2.54B | $2.58B |
| Total liabilities | $4.34B | $4.24B | $4.06B | $4.16B | $4.02B | $4.13B | $4.09B | $4.23B |
| Shareholders' equity | $8.33B | $8.24B | $8.36B | $8.24B | $8.35B | $8.29B | $8.13B | $8.08B |
| Net debt | $2.39B | $2.32B | $2.37B | $2.39B | $2.35B | $2.47B | $2.44B | $2.47B |
| Shares outstanding | 190.10M | 194.90M | 195.10M | 195.90M | 198.80M | 199.50M | 199.90M | 199.60M |
| Cash flow statement | ||||||||
| Operating cash flow | $341.70M | $182.80M | $260.90M | $247.90M | $261.40M | $96.20M | $190.60M | $268.10M |
| Capital expenditure | $68.70M | $86.40M | $102.20M | $98.00M | $96.90M | $78.10M | $89.40M | $140.00M |
| Free cash flow | $273.00M | $96.40M | $158.70M | $149.90M | $164.50M | $18.10M | $101.20M | $128.10M |
| Investing cash flow | -$69.80M | -$90.00M | -$102.90M | -$98.80M | -$98.10M | -$79.20M | -$96.80M | -$241.60M |
| Financing cash flow | -$252.90M | -$75.80M | -$147.90M | -$164.40M | -$156.30M | -$8.60M | -$96.60M | -$28.40M |
| Depreciation & amortization | $47.60M | $47.80M | $95.50M | $98.40M | $45.70M | $43.00M | $91.00M | $91.00M |
| Stock-based compensation | $15.90M | $15.50M | $19.20M | $15.20M | $16.20M | $20.30M | $18.80M | $16.40M |
| Dividends paid | — | — | — | — | — | — | — | $0 |
| Share buybacks | $339.20M | $15.50M | $92.50M | $196.80M | $52.70M | $40.60M | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 69 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.